Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)

Show other versions (1)

<h4>Background and aims</h4> Familial dysbetalipoproteinemia (FDBL) is a rare inborn lipid disorder characterized by the formation of abnormal triglyceride- and cholesterol-rich lipoproteins (remnant particles). Patients with FDBL have a high risk for atherosclerotic disease. The effect...

Full description

Bibliographic Details
Main Authors: Elisa Waldmann, Liya Wu, Kristina Busygina, Julia Altenhofer, Kerstin Henze, Alexander Folwaczny, Klaus G. Parhofer
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942248/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942248/?tool=EBI

Similar Items